Idiopathic inflammatory myositis

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 1, 2016, Pages 149-168

  Tieu, Joanna ^a   Lundberg, Ingrid E ^b   Limaye, Vidya ^a,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Dermatomyositis; Idiopathic inflammatory myopathy; Immune mediated necrotising myopathy; Inclusion body myositis; International Myositis Assessment and Clinical Studies group, IMACS; Necrotising myopathy; Polymyositis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ANTIBODY; ANTISYNTHETASE ANTIBODY; AUTOANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RITUXIMAB; UNCLASSIFIED DRUG;

CORTICOSTEROID THERAPY; DECISION MAKING; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; EVIDENCE BASED PRACTICE; HISTOPATHOLOGY; HUMAN; INCLUSION BODY MYOSITIS; LONGITUDINAL STUDY; MYOSITIS; NONHUMAN; OBSERVATIONAL STUDY; PLASMA EXCHANGE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; IMMUNOLOGY;

HUMANS; MYOSITIS; MYOSITIS, INCLUSION BODY;

EID: 84969980390     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.04.007     Document Type: Review

References (159)

1. [1] Gunawardena, H., Betteridge, Z.E., McHugh, N.J., Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20:6 (2008), 675–680.
2. [2] Targoff, I.N., Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 100:1 (1993), 116S–123S.
3. [3] Ghirardello, A., Zampieri, S., Tarricone, E., et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 39:3 (2006), 217–221.
4. [4] Koenig, M., Fritzler, M.J., Targoff, I.N., et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther, 9(4), 2007, R78.
5. [5] Limaye, V., Blumbergs, P., Scott, G., et al. The clinical features of dermatomyositis in a South Australian population. Int J Rheum Dis 10:2 (2007), 86–93.
6. [6] Troyanov, Y., Targoff, I.N., Tremblay, J.L., et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84:4 (2005), 231–249.
7. Love, L.A., Leff, R.L., Fraser, D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:6 (1991), 360–374.
8. [8] Chinoy, H., Payne, D., Poulton, K.V., et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology 48:10 (2009), 1213–1217.
9. [9] Arnett, F.C., Targoff, I.N., Mimori, T., et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 39:9 (1996), 1507–1508.
10. [10] Limaye, V.S., Lester, S., Bardy, P., et al. A three way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 32:3 (2012), 611–619.
11. [11] Bernstein, R.M., Autoantibodies in myositis. 1993.
12. [12] Hirakata, M., Suwa, A., Takada, T., et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 56:4 (2007), 1295–1303.
13. [13] Yamasaki, Y., Yamada, H., Nozaki, T., et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 54:6 (2006), 2004–2009.
14. [14] Hamaguchi, Y., Fujimoto, M., Matsushita, T., et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. Plos One, 8(4), 2013.
15. [15] Aggarwal, R., Cassidy, E., Fertig, N., et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:1 (2014), 227–232.
16. [16] Lefevre, G., Meyer, A., Launay, D., et al. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology 54:5 (2015), 927–932.
17. [17] Bodoki, L., Nagy-Vincze, M., Griger, Z., Dankó, K., Dermatomyositis-specific antibodies. Z Rheumatol 74:4 (2015), 363–369.
18. [18] Zhang, Y., LeRoy, G., Seelig, H.P., et al. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95:2 (1998), 279–289.
19. Ghirardello, A., Borella, E., Beggio, M., et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 5:3 (2014), 69–75.
20. [20] Muro, Y., Sugiura, K., Akiyama, M., Cutaneous manifestations in dermatomyositis: key clinical and serological features- a comprehensive review. Clin Rev Allergy Immunol, 2015, 1–10.
21. [21] Ghirardello, A., Zampieri, S., Iaccarino, L., et al. Anti-Mi-2 antibodies. Autoimmunity 38:1 (2005), 79–83.
22. [22] Sato, S., Hoshino, K., Satoh, T., et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:7 (2009), 2193–2200.
23. [23] Nakashima, R., Imura, Y., Kobayashi, S., et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 49:3 (2010), 433–440.
24. [24] Sato, S., Hirakata, M., Kuwana, M., et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:5 (2005), 1571–1576.
25. [25] Cao, H., Pan, M., Kang, Y., et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res 64:10 (2012), 1602–1610.
26. [26] Hall, J.C., Casciola-Rosen, L., Samedy, L.A., et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 65:8 (2013), 1307–1315.
27. [27] Hoshino, K., Muro, Y., Sugiura, K., et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49:9 (2010), 1726–1733.
28. [28] Moghadam-Kia, S., Oddis, C.V., Sato, S., et al. Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res 68:5 (2016), 689–694.
29. [29] Targoff, I.N., Mamyrova, G., Trieu, E.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54:11 (2006), 3682–3689.
30. [30] Kaji, K., Fujimoto, M., Hasegawa, M., et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46:1 (2007), 25–28.
31. [31] Trallero-Araguas, E., Rodrigo-Pendas, J.A., Selva-O'Callaghan, A., et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 64:2 (2012), 523–532.
32. [32] Aggarwal, R., Oddis, C.V., Goudeau, D., et al. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. Rheumatology 53:3 (2014), 433–437.
33. [33] Ichimura, Y., Matsushita, T., Hamaguchi, Y., et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:5 (2012), 710–713.
34. [34] Fiorentino, D.F., Chung, L.S., Christopher-Stine, L., et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65:11 (2013), 2954–2962.
35. [35] Tarricone, E., Ghirardello, A., Rampudda, M., et al. Anti-SAE antibodies in autoimmune myositis identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 384:1 (2012), 128–134.
36. [36] Betteridge, Z.E., Gunawardena, H., Chinoy, H., et al. Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann Rheum Dis 68:10 (2009), 1621–1625.
37. [37] Stenzel, W., Goebel, H.H., Aronica, E., Immune-mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features. Neuropathol App Neurobiol 2012:38 (2012), 632–646.
38. [38] Kao, A.H., Lacomis, D., Lucas, M., et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50 (2004), 209–215.
39. [39] Brouwer, R., Hengstman, G.J., Vree-Egberts, W., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:2 (2001), 116–123.
40. [40] Targoff, I.N., Johnson, A.E., Miller, F.W., Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33 (1990), 1361–1370.
41. [41] Miller, T., Al-Lozi, M.T., Lopate, G., et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:4 (2002), 420–428.
42. [42] Hengstman, G.J., Brouwer, R., Egberts, W.T., et al. Clinical and serological characteristics of 125 Dutch myositis patients: myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 249 (2002), 69–75.
43. [43] Hausmanowa-Petrusewicz, I., Kowalska-Oledzka, E., Miller, F.W., et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 40:7 (1997), 1257–1266.
44. [44] Hengstman, G.J., Ter Laak, H.J., Vree Egberts, W.T., et al. Anti-signal recognition particle autoantibodies: marker of necrotising myopathy. Ann Rheum Dis 65:12 (2006), 1635–1638.
45. [45] Suzuki, S., Nishikawa, A., Kuwana, M., et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 10(61), 2015.
46. Christopher-Stine, L., Casciola-Rosen, L.A., Hong, G., et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 (2010), 2757–2766.
47. [47] Mammen, A.L., Chung, T., Christopher-Stine, L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63:3 (2011), 713–721.
48. [48] Mammen, A.L., Gaudet, D., Brisson, D., et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res 64:8 (2012), 1233–1237.
49. [49] Limaye, V., Bundell, C., Hollingsworth, P., et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52:2 (2015), 196–203.
50. [50] Chung, T., Christopher-Stine, L., Paik, J.J., et al. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 52:2 (2015), 189–195.
51. [51] Mammen, A.L., Pak, K., Williams, E.K., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 64:2 (2012), 269–272.
52. [52] Werner, J.L., Christopher-Stine, L., Ghazarian, S.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Rheum 64:12 (2012), 4087–4093.
53. Mohassel, P., Mammen, A.L., The spectrum of statin myopathy. Curr Opin Rheumatol 25:6 (2013), 747–752.
54. [54] Larman, H.B., Salajegheh, M., Nazareno, R., et al. Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73:3 (2013), 408–418.
55. [55] Pluk, H., van Hoeve, B.J.A., van Dooren, S.H.J., et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol 73:3 (2013), 397–407.
56. Salajegheh, M., Lam, T., Greenberg, S.A., Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. Plos One, 6(5), 2011.
57. [57] Herbert, M.K., Stammen-Vogelzangs, Verbeek, M.M., et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 75:4 (2016), 696–701.
58. [58] Lloyd, T.E., Christopher-Stine, L., Pinal-Fernandez, I., et al. Cytosolic 5’-Nucleotidase 1A As a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken) 68:1 (2016), 66–71.
59. [59] Limaye, V.S., Lester, S., Blumbergs, P., et al. Anti-cN1A antibodies in South Australian patients with inclusion body myositis. Muscle Nerve 53:4 (2016), 654–655.
60. [60] Albrecht, I., Wick, C., Hallgren, Å., et al. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest 125:12 (2015), 4612–4624.
61. [61] Fiorentino, D.F., Presby, M., Baer, A.N., et al. PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. Ann Rheum Dis 75:6 (2016), 1145–1151.
62. [62] Hogg, J.R., Collins, K., Human Y5 RNA specializes a Ro ribonucleoprotein for 5S ribosomal RNA quality control. Genes Dev 21:23 (2007), 3067–3072.
63. [63] Cheng, L., Wang, P., Yang, S., et al. Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Med Genomics, 5(14), 2012.
64. [64] Ramakrishna, M., Williams, L.H., Boyle, S.E., et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. Plos One, 5(4), 2010.
65. [65] Dugar, M., Cox, S., Limaye, V., et al. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86:1012 (2010), 79–82.
66. [66] Ghillani, P., Andre, C., Toly, C., et al. Clinical significance of anti-Ro52 (TRIM 21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 10:9 (2011), 509–513.
67. [67] Schulte-Pelkum, J., Fritzler, M., Mahler, M., Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8:7 (2009), 632–637.
68. [68] Ferreira, J.P., Almeida, I., Marinho, A., et al. Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol, 2012, 2012.
69. [69] Mahler, M., Raijmakers, R., Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6:7 (2007), 432–437.
70. [70] Hanke, K., Bruckner, C.S., Dahnrich, C., et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther, 11(1), 2009, R22.
71. [71] Marie, I., Lahaze, L., Benveniste, O., et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 162:2 (2010), 337–344.
72. [72] Marie, I., Lahaxe, L., Tiev, K., et al. Idiopathic inflammatory myopathies with anti-PM-Scl antibodies: case series and literature review. Rev Med Interne 31:8 (2010), 540–544.
73. [73] Belizna, C., Henrion, D., Beuchner, A., et al. Anti-ku antibodies: clinical, genetic and diagnostic insights. Autoimmun Rev 9:10 (2010), 691–694.
74. [74] Franceschini, F., Cavazzana, I., Generali, D., et al. Anti-ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patietns. J Rheumatol 29:7 (2002), 1393–1397.
75. [75] Rigolet, A., Musset, L., Dubourg, O., et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 91:2 (2012), 95–102.
76. [76] Rutjes, S.A., Vree Egberts, W.T., Jongen, P., et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 209:1 (1997), 32–40.
77. [77] Yamasaki, Y., Satoh, M., Mizushima, M., et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol 26:3 (2016), 403–409.
78. [78] Dalakas, M.C., Polymyositis, dermatomyositis, and inclusion body myositis. NEJM 325 (1991), 1487–1498.
79. [79] Luo, Y.B., Mastaglia, F.L., Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 1852:4 (2015), 622–632.
80. [80] Hohlfeld, R., Polymyositis and dermatomyositis. Karpati, G., (eds.) Structural and molecular basis of skeletal muscle diseases, 2002, Neuropath Press, Switzerland, 221–227.
81. Pestronk, A., Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 23:6 (2011), 595–604.
82. [82] Hoogendijk, J.E., Amato, A.A., Lecky, B.R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromusc Disord 14:5 (2004), 337–345.
83. Dalakas, M.C., Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 40:4 pt 2 (2011), e237–e247.
84. [84] Dalakas, M.C., Hohlfeld, R., Polymyositis and dermatomyositis. Lancet 362 (2003), 971–982.
85. [85] Nogalska, A., Terracciano, C., D'Agostino, C., et al. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 118:3 (2009), 407–413.
86. [86] Brady, S., Squier, W., Sewry, C., et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open, 4(4), 2014.
87. Mastaglia, F.L., Needham, M., Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 22:1 (2015), 6–13.
88. [88] Lindgren, U., Roos, S., Hedberg Oldfors, C., et al. Mitochondtrial pathology in inclusion body myositis. Neuromusc Disord 25:4 (2015), 281–288.
89. [89] Rose, M.R., ENMC IBM Working Group, 188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromusc Disord 23:12 (2013), 1044–1055.
90. [90] Sadeh, M., Dabby, R., Steroid-responsive myopathy: immune-mediated necrotizing myopathy or polymyositis without inflammation?. J Clin Neuromuscul Dis 9:3 (2008), 341–344.
91. [91] Bronner, I.M., Hoogendijk, J.E., Wintzen, A.R., et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 250:4 (2003), 480–485.
92. [92] Matsubara, S., Hirai, S., Sawa, Y., Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol 76:1–2 (1997), 75–80.
93. [93] Hohlfeld, R., Engel, A.G., The immunobiology of muscle. Immunol Today 15:6 (1994), 269–274.
94. [94] Nagaraju, K., Raben, N., Merritt, G., et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 113 (1998), 407–414.
95. [95] Nagaraju, K., Casciola-Rosen, L., Lundberg, I., et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52:6 (2005), 1824–1835.
96. [96] Tajima, Y., Moriwaka, F., Tashiro, K., Temporal alterations of immunohistochemical findings in polymyositis. Intern Med 33:5 (1994), 263–270.
97. [97] Dalakas, M.C., Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 10:3 (2010), 346–352.
98. [98] Civatte, M., Schleinitz, N., Krammer, P., et al. Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol App Neurobiol 29:6 (2003), 546–552.
99. [99] Goebels, N., Michaclis, D., Wekerle, H., et al. Human myoblasts as antigen-presenting cells. J Immunol 149:2 (1992), 661–667.
100. [100] Das, L., Blumbergs, P.C., Manavis, J., et al. Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy. Appl Immunohistochem Mol Morphol 21:6 (2013), 539–542.
101. [101] Rodríguez Cruz, P.M., Luo, Y.B., Miller, J., et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromusc Disord 24:12 (2014), 1025–1035.
102. [102] Salaroli, R., Baldin, E., Papa, V., et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. J Clin Path 65:1 (2012), 14–19.
103. [103] Mescam-Mancini, L., Allenbach, Y., Hervier, B., et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 138:Pt 9 (2015), 2485–2492.
104. [104] Jain, A., Sharma, M.C., Sarkar, C., et al. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand 123:2 (2011), 122–129.
105. [105] Panicker, J.B., Chacko, G., Patil, A.K., et al. Immunohistochemical differentiation of inflammatory myopathies. Neurol India 59:4 (2011), 513–520.
106. [106] Choi, J.H., Park, Y.E., Kim, S.I., et al. Differential immunohistological features of inflammatory myopathies and dysferlinopathy. J Korean Med Sci 24:6 (2009), 1015–1023.
107. [107] Brunn, A., Schröder, R., Deckert, M., The inflammatory reaction pattern distinguishes primary dysferlinopathies from idiopathic inflammatory myopathies: an important role for the membrane attack complex. Acta Neuropathol 112:3 (2006), 325–332.
108. [108] Confalonieri, P., Oliva, L., Andreetta, F., et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 142:1–2 (2003), 130–136.
109. [109] Askanas, V., Engel, W.K., Nogalska, A., Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 39:7 (2012), 736–749.
110. [110] Girolamo, F., Lia, A., Amati, A., et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol App Neurobiol 39:7 (2013), 736–749.
111. [111] Bjørkøy, G., Lamark, T., Johansen, T., p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2:2 (2006), 138–139.
112. [112] Seibenhener, M.L., Babu, J.R., Geetha, T., et al. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:18 (2004), 8055–8068.
113. [113] Hiniker, A., Daniels, B.H., Lee, H.S., et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun, 1(1), 2013, 29.
114. [114] Suber, T.L., Casciola-Rosen, L., Rosen, A., Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 4:4 (2008), 201–209.
115. [115] Aouizerate, J., De Antonio, M., Bassez, G., et al. Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun, 23(2), 2014, 154.
116. [116] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). NEJM 292 (1975), 403–407.
117. [117] Pinal-Fernandez, I., Casciola-Rosen, L.A., Christopher-Stine, L., et al. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42:8 (2015), 1448–1454.
118. [118] Fiorentino, D., Chung, L., Zwerner, J., et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65 (2011), 25–34.
119. [119] Paik, J.J., Wigley, F.M., Lloyd, T.E., et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken) 67:10 (2015), 1416–1425.
120. [120] Jakati, S., Rajasekhar, L., Uppin, M., et al. SLE myopathy: a clinicopathological study. Int J Rheumatic Dis 18:8 (2015), 886–891.
121. [121] International myosisitis assessment & clinical studies group (IMACS): global approaches to improved treatments and understanding of myositis.: National Institute of Environmental Health Sciences; [cited 2015]. Available from: http://www.niehs.nih.gov/research/resources/imacs/index.cfm.
122. [122] Rider, L.G., Weth, V.P., Huber, A.M., et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63:Suppl. 11 (2011), S118–S157.
123. [123] Rider, L.G., Giannini, E.H., Brunner, H.I., et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50:7 (2004), 2281–2290.
124. [124] Joffe, M.M., Love, L.A., Leff, R.L., et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:4 (1993), 379–387.
125. [125] Vd, Vlekkert, Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised controlled trial. Neuromusc Disord 20:6 (2010), 382–389.
126. [126] J. V. Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (prometheus). NCT00651040. clinicaltrials.gov2013.
127. [127] Badrising, U.A., Maat-Schieman, M.L.C., Ferrari, M.D., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51:3 (2002), 369–372.
128. [128] Hornung, T., Ko, A., Tuting, T., et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol 37 (2011), 139–142.
129. [129] Bunch, T.W., Worthington, J.W., Combs, J.J., et al. Azathioprine with prednisone for polymyositis. Ann Intern Med 92 (1980), 365–369.
130. [130] Bunch, T.W., Prednisone and azathioprine for polymyositis. Arthritis Rheum 24:1 (1981), 45–48.
131. [131] Valiyll, R., Casciola-Rosen, L., Hong, G., et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62:9 (2010), 1328–1334.
132. [132] Allenbach, Y., Drouot, L., Rigolet, A., et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93:3 (2014), 150–157.
133. [133] Danieli, M.G., Malcangi, G., Palmieri, C., et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61 (2002), 37–41.
134. [134] Vencovsky, J., Jarosova, K., Machacek, S., et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29 (2000), 95–102.
135. [135] Villalba, L., Hicks, J.E., Adams, E.M., et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:3 (1998), 392–399.
136. Oddis, C.V., Reed, A.M., Aggarwal, R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 65:2 (2013), 314–324.
137. [137] Allenbach, Y., Guiguet, M., Rigolet, A., et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase III trial. PlosOne, 10(11), 2015.
138. [138] Couderc, M., Gottenberg, J.E., Mariette, X., et al. Efficacy and safety of rituximab in the treatment of refractoy inflammatory myopathies in adults: results from the AIR registry. Rheumatology 50 (2011), 2283–2289.
139. [139] Mahler, E.A.M., Blom, M., Voermans, N.C., et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 50 (2011), 2206–2213.
140. [140] Levine, T.D., Rituximab in the treatment of dermatomyositis. Arthritis Rheum 52:2 (2005), 601–607.
141. [141] Unger, L., Kampf, S., Luthke, K., et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology 53 (2014), 1630–1638.
142. [142] Aggarwal, R., Bandos, A., Reed, A.M., et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66:3 (2014), 740–749.
143. [143] Whelan, B., Isenberg, D.A., Poor response of anti-SRP positive idiopathic immune myositis to B-cell depletion [letter]. Rheumatology 48 (2009), 594–595.
144. [144] Arlet, J.B., Dimitri, D., Pagnoux, C., et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromusc Disord 16:5 (2006), 334–336.
145. [145] Dalakas, M.C., Illa, I., Dambrosia, J.M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. NEJM 329:27 (1993), 1993–2000.
146. [146] Dalakas, M.C., Sonies, B., Dambrosia, J., et al. Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology 48:3 (1997), 712–716.
147. [147] Marie, I., Menard, J.F., Hatron, P.Y., et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res 62:12 (2010), 1748–1785.
148. [148] Blakewell, C.J., Raghu, G., Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest, 139, 2011.
149. [149] Suzuki, Y., Kayakawa, H., Miwa, S., et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:3 (2009), 201–206.
150. Mammen, A.L., Tiniakou, E., Intravenous immune globulin for statin-triggered autoimmune myopathy. NEJM 373 (2015), 1680–1682.
151. [151] Miller, F.W., Leitman, S.F., Cronin, M.E., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. NEJM 326 (1992), 1380–1384.
152. [152] Alexanderson, H., Munters, L.A., Dastmalchi, M., et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis – a randomized controlled single-blinded study with a 2-year followup. J Rheumatol 41:6 (2014), 1124–1132.
153. [153] Munters, L.A., Loell, I., Ossipova, E., et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol, 2016 Feb 11, 10.1002/art.39624 [Epub ahead of print].
154. [154] Alemo Munters, L., Dastmalchi, M., Katz, A., et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther, 15(4), 2013, R83.
155. [155] Alemo Munters, L., Dastmalchi, M., Andgren, V., et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) 65:12 (2013), 1959–1968.
156. [156] Bronner, I.M., van der Meulen, M.F., de Visser, M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65:11 (2006), 1456–1461.
157. [157] Danieli, M.G., Gambini, S., Pettinari, L., et al. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev 13:10 (2014), 1048–1054.
158. [158] EuroMyositis: international collaboration research and treatment database for myositis specialists: EuroMyositis; [cited 2015]. Available from: www.euromyositis.eu.
159. [159] Rothwell, S., Cooper, R.G., Lundberg, I.E., et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis, 2015 Sep 11, 10.1136/annrheumdis-2015-208119 [Epub ahead of print].